Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 34 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009;374:744-55. [Ref.ID 86653]
2.Tiene citas relacionadas Cita con resumen
Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-43. [Ref.ID 86652]
3. Cita con resumen
Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17. [Ref.ID 85954]
5.
Barnes PJ. Future treatments. BMJ 2006;333:246-8. [Ref.ID 77778]
6.Tiene citas relacionadas Cita con resumen
Barnes PJ, Kleinert S. COPD - a neglected disease. Lancet 2004;364:564-5. [Ref.ID 70994]
7. Cita con resumen
Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-3. [Ref.ID 69299]
8.
Barnes PJ, Adcock IM. How do corticosteroids work in asthma?. Ann Intern Med 2003;139:359-70. [Ref.ID 67293]
9.
Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002;42:81-98. [Ref.ID 64270]
10.Tiene citas relacionadas
Robinson D, Campbell DA, Barnes PJ. Montelukast for persistent asthma. Authors' reply. Lancet 2001;358:1455-6. [Ref.ID 58793]
12.Tiene citas relacionadas
Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, Warrington SJ, Renzetti L, Rames A, Brock JA, Boyce MJ, Hansel TT, Holgate ST, Barnes PJ. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2149-53. [Ref.ID 56256]
13.Tiene citas relacionadas
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8. [Ref.ID 54258]
14.
Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80. [Ref.ID 52218]
15.Tiene citas relacionadas Cita con resumen
Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, for the Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet 2000;355:1675-9. [Ref.ID 50954]
16.Tiene citas relacionadas
Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med 1999;341:2006-8. [Ref.ID 48581]
17.Tiene citas relacionadas
Barnes PJ. Salmeterol/fluticasone propionate combination: viewpoint. Drugs 1999;57:942-3. [Ref.ID 45183]
18.Tiene citas relacionadas
Evans DJ, Taylor DA, Zetterström O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8. [Ref.ID 35519]
19.Tiene citas relacionadas
Pauwels R A, Löfdahl C-G, Postma D S, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11. [Ref.ID 35518]
20.
Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996;42:3-10. [Ref.ID 28189]
Seleccionar todas
 
 1 a 20 de 34 siguiente >>